Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 89.4% in November

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 42,000 shares, a drop of 89.4% from the October 31st total of 396,100 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily volume of 263,800 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Trading of Xilio Therapeutics

A number of large investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in Xilio Therapeutics by 85.0% in the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after buying an additional 155,337 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Xilio Therapeutics in the second quarter valued at approximately $32,000. Finally, Renaissance Technologies LLC raised its stake in shares of Xilio Therapeutics by 18.3% in the second quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock valued at $280,000 after acquiring an additional 45,554 shares during the last quarter. 54.29% of the stock is currently owned by institutional investors.

Xilio Therapeutics Trading Up 1.8 %

Shares of XLO opened at $1.01 on Friday. The stock has a market cap of $44.40 million, a PE ratio of -0.59 and a beta of -0.24. Xilio Therapeutics has a 1 year low of $0.49 and a 1 year high of $1.93. The stock has a 50 day simple moving average of $0.93 and a 200-day simple moving average of $0.94.

Analyst Ratings Changes

Separately, Raymond James decreased their target price on shares of Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.